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a b s t r a c t
The effects of acute treatment with sibutramine on the peripheral sympathetic neurotransmission in vas
deferens of young rats were still not evaluated. Therefore, we carried out this study in order to verify the
effects of acute sibutramine treatment on the neuronal- and exogenous agonist-induced contractions
of the young rat vas deferens. Young 45-day-old male Wistar rats were pretreated with sibutramine
6 mg/kg and after 4 h the vas deferens was used for experiment. The acute treatment with sibutramine
was able to increase the potency (pD2) of noradrenaline and phenylephrine. Moreover, the efﬁcacy (Emax)
of noradrenaline was increased while the efﬁcacy of serotonin and nicotine were decreased.
The maximum effect induced by a single concentration of tyramine was diminished in the vas deferens
from treated group. Moreover, the leftward shift of the noradrenaline curves promoted by uptake
blockers (cocaine and corticosterone) and β-adrenoceptor antagonist (propranolol) was reduced in the
vas deferens of treated group. The initial phasic and secondary tonic components of the neuronal-evoked
contractions of vas deferens from treated group at the frequencies of 2 Hz were decreased. Moreover,
only the initial phasic component at 5 Hz was diminished by the acute treatment with sibutramine.
In conclusion, we showed that the acute treatment with sibutramine in young rats was able to affect the
peripheral sympathetic nervous system by inhibition of noradrenaline uptake and reduction of the
neuronal content of this neurotransmitter, leading to an enhancement of vas deferens sensitivity to
noradrenaline.
& 2014 Elsevier B.V. All rights reserved.
1. Introduction
Overweight and obesity among children and adolescents is
considered a global public health epidemic (Kanekar and Sharma,
2010). Moreover, strong evidences suggest that the pharmacolo-
gical intervention in obese youngster could avoid several comor-
bidities in their adulthood (Viner et al., 2009). In this context,
sibutramine has been described in clinical trials as a valid
therapeutic option for the management of obesity among children
and adolescents (Kanekar and Sharma, 2010).
Sibutramine is an anti-obesity drug that exerts its pharmaco-
logical actions by inhibiting the reuptake of serotonin and noradre-
naline in the central nervous system, mainly in the hypothalamus
(Fletcher et al., 2010) leading to the energy expenditure increase and
food intake decrease by enhancing satiety (Finer, 2002). Sibutramine
is commonly considered a safe and well tolerated agent, but it may
cause several side effects on cardiovascular system (Scheen, 2010)
and on male reproduction, both related to the peripheral sympatho-
mimetic actions of this drug (Padwal and Majumdar, 2007; Nojimoto
et al., 2009; Borges et al., 2013). Because of the cardiovascular risk,
in 2010 sibutramine was withdrawn from European and North
American market by European Medicines Agency (EMEA) and Food
and Drug Administration (FDA) (Scheen, 2011). However, it is still
marketed in several countries, including Brazil (Mariotti et al., 2013).
The indirect peripheral sympathomimetic actions of sibutramine
on reproductive system is manifested by the greatly increased
potency of noradrenaline in inducing contractions of the adult rat
vas deferens and seminal vesicle, leading to an abnormal ejacula-
tion (Nojimoto et al., 2009). Additionally, sibutramine promoted
an acceleration of sperm transit time in epididymal cauda, and a
decrease of the quality and quantity of sperm reserves in adult
rodents (Bellentani et al., 2011; Borges et al., 2013).
Previous study from our laboratory showed that the acute
sibutramine treatment increase the calcium-induced contraction
by the L-type voltage-gated calcium channels in vas deferens from
young rats (Jurkiewicz et al., 2012). Nevertheless, the effect of
Contents lists available at ScienceDirect
journal homepage: www.elsevier.com/locate/ejphar
European Journal of Pharmacology
http://dx.doi.org/10.1016/j.ejphar.2014.05.035
0014-2999/& 2014 Elsevier B.V. All rights reserved.
n Corresponding author. Tel./fax: þ55 11 5576 4449.
E-mail address: aron.farm@epm.br (A. Jurkiewicz).
European Journal of Pharmacology 738 (2014) 118–124
acute sibutramine treatment on the peripheral sympathetic neu-
rotransmission of young rat vas deferens was still not established.
Therefore, due to the few studies that emphasize the in vivo
acute treatment with sibutramine in young animals, and its
consequences on the peripheral sympathetic neurotransmission,
we carried out a study in order to further evaluate the effects
of acute sibutramine treatment on the neuronal and exogenous
agonist-induced contractions of the young rat vas deferens. In the
present work we have analyzed the effects of acute treatment with
sibutramine in the contractions of young rat vas deferens induced
by noradrenaline in the absence or presence of uptake blockers
(cocaine and corticosterone) and β-adrenoceptor antagonist (pro-
pranolol), phenylephrine, serotonin, nicotine and tyramine or by
endogenous neurotransmitters released from nerve terminals by
electrical ﬁeld stimulation (EFS).
2. Materials and methods
2.1. Animals and treatment
Young male Wistar, 45 days-old rats, from our colony (INFAR)
were treated with a single dose of sibutramine 6 mg/kg (diluted in
distilled water) by oral gavage or distilled water (control group).
The dose of 6 mg/kg was chosen following previous studies in the
literature that used similar doses to study the effects of sibutra-
mine in rats, mainly in peripheral nervous system (Nojimoto et al.,
2009; Bellentani et al., 2011; Francia-Farje et al., 2010). Four hours
after acute treatment, rats were killed by decapitation, followed by
the removal and isolation of vas deferens for functional experi-
ments. The 4 h interval of treatment was chosen based on the half-
life of sibutramine and the formation of its active metabolites, that
for rodents have plasmatic pick between 2 and 3 h (Noh et al.,
2010), presenting a high plasmatic concentration in the moment of
the experiment. All experimental procedures were approved by
Ethics Committee of Unifesp (protocol number 0015/13).
2.2. Functional experiments
2.2.1. Standard isolated organ bath preparation
Following isolation, the whole vas deferens was mounted
under 1 g tension in a 10 ml organ bath containing a nutrient
solution with composition (mM): 138 NaCl; 5.7 KCl; 1.8 CaCl2; 0.36
NaH2PO4; 15 NaHCO3 and 5.5 glucose, prepared in glass distilled
deionized water bubbled with air, and maintained under 32 1C,
pH 7.3 (Picarelli et al., 1962). Changes of isometric tension were
digitally recorded by attaching one end of the vas deferens to a
force-displacement transducer (CB Science, mod FT 302, USA)
connected through a bridge ampliﬁer to a PowerLab recording
system (AD Instruments, Castle Hill, Australia), coupled to a computer.
Data were stored by means of Chart version 4.2.1 software
(AD Instruments, Castle Hill, Australia).
2.2.2. Concentration–response curves for agonists
The vas deferens was mounted as described above. After a
stabilization period of 30 min, concentration–response curves
were performed for noradrenaline, phenylephrine, serotonin or
nicotine by the cumulative addition of the agonists to the organ
bath. Moreover, cumulative concentration–response curves for
noradrenaline were performed in the absence or presence of a
mixture composed by cocaine (6106 M), corticosterone
(105 M) and propranolol (107 M) pre-incubated for 30 min in
order to check the participation of noradrenaline uptake system
(neuronal and extra-neuronal uptake) and β-adrenoceptors.
Furthermore, the effect of a single concentration of tyramine
(104 M, for 3 min) was performed to evaluate the release of
noradrenaline from sympathetic nerve endings (Langeloh and
Trendelenburg, 1987).
2.2.3. Neurogenic contractions
For the study of nerve-mediated contractions the vas deferens
was mounted as described above and placed between two parallel
platinum electrodes connected to an electrical stimulator Grass
S88 (Grass, USA) inducing an electrical ﬁeld stimulation (EFS)
(Vladimirova et al., 1994). After an equilibration period of 30 min,
the tissues were subjected to electrical ﬁeld stimulation of 60 V,
1 ms duration, and 2 and 5 Hz, by means of a Grass S88 stimulator
(Grass USA). For each frequency, the initial phasic (purinergic
contraction) and the secondary tonic (noradrenergic contraction)
components were measured (Fig. 1) (Westfall and Westfall, 2001;
Burnstock and Verkhratsky, 2010).
2.3. Pharmacological parameters
The pharmacological parameters Emax (efﬁcacy, indicated by
the maximum contraction induced by a full agonist) (Jurkiewicz
and Jurkiewicz, 1976) and pD2 (potency, indicated by the negative
Log of EC50) (Jurkiewicz et al., 1977), were calculated to allow
comparisons between curves noradrenaline, phenylephrine, ser-
otonin and nicotine from control and treated groups. In addition,
the concentration-ratio (CR¼EC50a/EC50b; the ratio between EC50
of the agonist in the absence of blockers and EC50 of the agonist in
the presence of blockers) was measured to quantify the potentiation
of noradrenaline concentration–response curves after the addition
of the noradrenaline system blockers and β-adrenoceptor antago-
nist, as described above (Section 2.2.2).
2.4. Drugs and reagents
Drugs were obtained from the following sources: sibutramine
hydrochloride monohydrate, tyramine hydrochloride, ()-nicotine,
(7)-norepinephrine (þ)-bitartarate salt, serotonin hydrochloride,
Fig. 1. Record of the contractile response of young rat vas deferens induced by
electrical ﬁeld stimulation (EFS) at frequencies of 2 and 5 Hz. The neuronal-evoked
vas deferens contraction at 2 and 5 Hz is composed by an initial rapid component
(PR: initial phasic response) followed by a maintained component (TR: secondary
tonic response).
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L-phenylephrine hydrochloride, propranolol hydrochloride, corticoster-
one all from Sigma-Aldrich (MO, USA). Cocaine was gently donated by
the Núcleo de Exames e Entorpecentes do Instituto de Criminalística
da Polícia Técnico-Cientíﬁca do Estado de São Paulo. All reagents used
for nutrient solutions were from Merck (Brazil).
2.5. Data and statistical analysis
The data were calculated as a g of tension and curve ﬁtting by non-
linear regression for the calculation of pD2 and Emax was performed
with Prism v.5 software (GraphPAD Software, San Diego, CA, USA).
The values were presented as means7standard error of mean
(S.E.M.) and the Student's t-tests were used for the comparisons
between groups. A P value of less than 0.05 was considered to be
statistically signiﬁcant. The results were obtained from at least
5 (n) independent experiments performed with tissues from
different animals.
3. Results
3.1. Cumulative concentration–response curves for agonists
Fig. 2 shows the log-concentration–response curves for nora-
drenaline, phenylephrine, serotonin and nicotine obtained from
young rat vas deferens treated with sibutramine or vehicle (con-
trol). The acute treatment with sibutramine was able to increase
the potency (pD2) of noradrenaline and phenylephrine by about
4 and 3-fold, respectively, as distinguished by a leftward shift in
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Fig. 2. Non-linear regression of the contractile responses obtained from cumulative concentration–response curves for noradrenaline (A), phenylephrine (B), serotonin
(C) and nicotine (D) in vas deferens of 45-day-old rats treated with sibutramine 6 mg/kg. v.o. (□) and their respective controls (●) treated with distilled water. Values are
means7S.E.M. of 5–14 independent experiments performed with tissues from different rats. *Po0.05 in relation to control (unpaired t-test).
Table 1
Maximal contraction (Emax) and potency (pD2) values (means7S.E.M.) from
cumulative concentration–response curves for noradrenaline, phenylephrine, ser-
otonin and nicotine in vas deferens of 45-day-old rats treated with sibutramine
6 mg/kg v.o. and their respective controls.
Agonists Parameters Cumlative concentration–response curves
Control Sibutramine 6 mg/kg
Noradrenaline Emax 1.3670.05 (10) 1.8370.05 (13)a
pD2 5.7370.10 (10) 6.3170.1 (13)a
Phenylephrine Emax 1.4270.06 (14) 1.3370.04 (14)
pD2 5.8470.13 (14) 6.370.11 (14)a
Serotonin Emax 0.7370.04 (6) 0.5070.03 (6)a
pD2 6.4270.14 (6) 6.6770.20 (6)
Nicotine Emax 2.670.05 (5) 2.170.09 (6)a
pD2 4.3070.05 (5) 4.3870.05 (6)
Emax (maximal contraction) expressed in gram of tension and pD2 (apparent afﬁnity
of the agonists indicating potency, measured as the negative Log of EC50) obtained
from the non-linear regression curves shown in Fig. 1. (n)¼number of experiments.
a Po0.05 in relation control.
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the concentration–response curve (Fig. 2A and B). Moreover, the
efﬁcacy (Emax) of noradrenaline was increased by about 25% while
the efﬁcacy of serotonin (Fig. 2C) and nicotine (Fig. 2D) were
decreased by about 30% and 10%, respectively. The corresponding
values of Emax and pD2 for each agonist are shown in Table 1.
3.2. Tyramine-induced contractions in young rat vas deferens
Tyramine, an indirect sympathomimetic drug, is able to release
noradrenaline from the sympathetic varicosities and can be used
to determine indirectly the neuronal content of this neurotrans-
mitter. As shown in Fig. 3A, the vas deferens from animal treated
with sibutramine showed a delay to reach the maximum contrac-
tile effect evoked by a single concentration of tyramine (104 M,
3 min) when compared with control group. Furthermore, the
maximum effect induced by tyramine was diminished in the vas
deferens from treated group by about 20%, suggesting that
sibutramine treatment was able to reduce de neuronal content
of noradrenaline (Fig. 3B).
3.3. Effect of the uptake blockers and β-adrenoceptor antagonist on
the noradrenaline-induced contractions
In order to check the involvement of uptake system (neuronal
and extraneuronal uptake) and β-adrenoceptors in the effects
induced by the sibutramine treatment in the young rat vas
deferens, noradrenaline curves were constructed in the absence
or presence of a mixture composed by cocaine, corticosterone
and propranolol. The presence of these blockers potentiated the
noradrenaline-induced contractions, as reﬂected by the leftward
shift in the concentration–response curves in both groups (Fig. 4)
without changing the maximum contractile effect for this agonist.
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Fig. 3. Effect of a single concentration of tyramine (104 M, for 3 min) in the vas deferens of 45-day-old rats treated with sibutramine 6 mg/kg. v.o. and their respective
controls: (A) original tracings showing the contractions in response to tyramine (104 M, for 3 min) in the vas deferens of young rats treated with sibutramine 6 mg/kg. v.o.
(lower graph) and their respective controls (upper graph). (B) Bar graph showing the maximum contractile effects (g of tension) induced by tyramine (104 M, for 3 min) in
the vas deferens of young rats treated with sibutramine 6 mg/kg v.o. (gray bar) and their respective controls (white bar). Each bar represents the means7S.E.M. of 16
independent experiments performed with tissues from different rats. *Po0.05 in relation to control (unpaired t-test).
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Fig. 4. Non-linear regression of the contractile responses obtained from cumulative concentration–response curves for noradrenaline in the absence (●) or presence (□) of
mixture composed by cocaine (6106 M), corticosterone (105 M) and propranolol (107 M) in the vas deferens of 45-day-old rats treated with sibutramine 6 mg/kgv.o.
(B) and their respective controls (A). Values are means7S.E.M. of 12–14 independent experiments performed with tissues from different rats.
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However, the leftward shift of the noradrenaline curves promoted
by the mixture was markedly reduced (by about 85%) in the vas
deferens of animals treated with sibutramine (Fig. 4B) compared
with control (Fig. 4A), as determined by the concentration-ratio
values shown in Table 2.
3.4. Neurogenic contractions
Neurogenic contractions induced by electrical ﬁeld stimulation
in vas deferens have two phases, namely initial phasic (purinergic,
ATP-dependent) and secondary tonic (noradrenergic, noradrena-
line-dependent) component (Fig. 1) (Westfall and Westfall, 2001).
Fig. 5A shows that the acute sibutramine treatment was able to
decrease the initial phasic and secondary tonic components of the
neuronal-evoked contractions of vas deferens at the frequencies of
2 Hz by about 30% and 35%, respectively. On the other hand, only
the initial phasic component at 5 Hz was diminished (20%) by the
acute treatment with sibutramine (Fig. 5B).
4. Discussion
In this study we have shown that the treatment with sibutra-
mine when administered in young rats in vivo during 4 h affected
the vas deferens contractions induced by agonists (noradrenaline,
phenylephrine, serotonin and nicotine), tyramine and electrical
ﬁeld stimulation. Moreover, the leftward shift of noradrenaline
curves promoted by inhibitors of neuronal (cocaine), extra-
neuronal uptake (corticosterone) and β-adrenoceptors (propranolol)
was dramatically reduced after the acute treatment with sibutramine.
It is well established that sibutramine inhibits the neuronal
uptake of noradrenaline and serotonin in the central nervous
system, but its peripheral effects have not been well evaluated,
mainly in young experimental models. The acute treatment with
sibutramine 6 mg/kg was able to increase the potency (pD2) and
maximal contractile effect (Emax) for noradrenaline in young rat
vas deferens. Indeed, recent studies have shown that in vitro
treatment with sibutramine is able to increase the potency to
noradrenaline in adult vas deferens, epididymis and prostate and
these effects are ascribed to the blockade of neuronal uptake of
noradrenaline induced by this drug (Nojimoto et al., 2009; Borges
et al., 2013). Moreover, previous study from our laboratory showed
that the acute treatment with sibutramine increased the calcium
transients and the calcium-induced contractions of young rat vas
deferens by a mechanism dependent of L-type voltage-gated
calcium channels (Jurkiewicz et al., 2012). Therefore, the increased
potency and maximal effect for noradrenaline in vas deferens from
treated young rats could be related to the neuronal uptake
blockade and to the increase of calcium sensitivity induced by
sibutramine.
The saturable uptake process (neuronal or extraneuronal
uptake) of catecholamines is an important physiological mechan-
ism that regulates the vas deferens sensitivity to noradrenaline
(Kasuya et al., 1969; Chies et al., 2003). For instance, in a tissue
with a noradrenaline uptake process, a fraction of the noradrena-
line added to the organ bath will not reach the receptors and a
steady-state deﬁcit of agonist between organ bath and receptor
compartment will develop. Therefore, the concentration–response
curve will be less potent than the true curve. On the other hand,
the blockade of uptake process decreases the fraction of noradre-
naline taken up by sympathetic nerve endings, increasing the
agonist concentration in the receptor compartment and potentiat-
ing the noradrenaline curves (Kenakin, 1980).
Then, in order to verify whether the acute in vivo treatment
with sibutramine in young rats is able to affect the uptake system,
a mixture with neuronal and extraneuronal uptake blockers were
added to the organ bath, and then a cumulative-concentration–
response-curve for noradrenaline was constructed. Propranolol
was added to the mixture to increase the available noradrenaline
for α1-adrenoceptors or uptake system and avoid its probable
action on pre or postsynaptic β-adrenoceptors (Diaz-Toledo and
Jurkiewicz, 1991; Koslov and Andersson, 2013).
In fact, the mixture composed by cocaine, corticosterone and
propranolol leftward shifted noradrenaline curves without chan-
ging Emax parameter. However, in the tissues from sibutramine-
treated rats, the potentiation of noradrenaline curves was reduced,
indicating that the acute treatment of sibutramine might affect the
catecholamine uptake system.
In addition, the maximal effect for nicotine and serotonin-
induced vas deferens contractions were decreased by the acute
treatment with sibutramine. Both nicotine and serotonin induced
contractions of the rat vas deferens by the activation of pre-
synaptic nicotinic and serotoninergic receptor, respectively, lead-
ing to the release of catecholamines from the terminal nerve
endings (Arefolov et al., 1976; von Kugelgen and Starke, 1991;
Jurkiewicz et al., 1999). Thus, these results strongly indicate
that the acute treatment with sibutramine induced a reduction
of catecholamine neuronal content in the young rat vas deferens.
The hypothesis that the acute treatment with sibutramine
decreases the neuronal content of catecholamines is also sup-
ported by the tyramine-induced contractions. Tyramine, an indir-
ect sympathomimetic drug, is taken up by the sympathetic
varicosity and is subsequently stored in synaptic vesicles, promot-
ing the release of the noradrenaline (Brandao et al., 1980). The
results found in isolated vas deferens of young rats treated with
sibutramine showed a reduction on tyramine-induced contraction
and a noticeably slowing kinetic until reaching its maximal
tension, which can be due to an interference of neuronal uptake
sites by sibutramine added to a decrease of noradrenaline content
in the sympathetic varicosities.
To conﬁrm the interference of neuronal uptake process exerted
by the acute treatment with sibutramine, nerve-evoked contrac-
tions were performed in young rat vas deferens from both the
groups. The blockade of uptake process by cocaine is able to
decrease the initial phasic contraction whereas the secondary
tonic contraction for electrical driven vas deferens from adult
animals is increased. The mechanism underlying this effect is
attributed to the increase of noradrenaline concentration in
biophase leading to excessive activation of pre-synaptic inhibitory
α2-adrenoceptors (diminishing the ATP release and initial phasic
Table 2
Values (means7S.E.M.) of concentration-ratio (CR¼EC50a/EC50b) obtained from
the EC50 of the noradrenaline in the absence (EC50a) or presence (EC50a) of a
mixture composed by cocaine, corticosterone and propranolol. Maximal effects
(g of tension) for noradrenaline in absence (Emaxa) or presence (Emaxb) of mixture.
Parameters Control (n¼14) Sibutramine (n¼12)
EC50a 2.0670.26 mM 0.4170.09 mM
Emaxa 1.4070.05 1.7970.05ª
EC50b 0.1070.03 mM 0.1570.05 mM
Emaxb 1.4670.03 1.6070.05ª
CR (EC50a/EC50b) 20.7476.0 2.7670.76ª
EC50a: EC50 of the agonist in the absence of cocaine, corticosterone and propranolol.
Emaxa: Maximum effect of the agonist (in gram of tension) in the absence of
cocaine, corticosterone and propranolol.
EC50b: EC50 of the agonist in the presence of cocaine, corticosterone and propra-
nolol.
Emaxb: Maximum effect (in gram of tension) of the agonist in the presence of
cocaine, corticosterone and propranolol.
CR: concentration ratio.
n¼number of experiments.
a Po0.05 in relation control.
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response) and postsynaptic α1-adrenoceptors (increasing the sec-
ondary tonic response) (Todorov et al., 1996).
As expected, the initial phasic (purinergic, ATP-dependent)
component was also decreased at frequencies of 2 and 5 Hz in
the treated group. However, at frequency of 2 Hz, secondary tonic
(noradrenergic, noradrenaline-dependent) component of nerve
evoked contractions were diminished in the vas deferens from
young rats submitted to the acute treatment with sibutramine.
The decrease in the secondary tonic component might be
explained by the age of the rats used in this study. In fact, the
sympathetic neurotransmission in the young rat vas deferens (3–4
weeks) lacks the adrenergic component, although the purinergic
component is present (MacDonald and McGrath, 1984). Thus, this
situation is very similar to the response of prostatic portion of vas
deferens from adult animals which are more responsive to ATP
(Westfall and Westfall, 2001). In the presence of uptake process
blockers, the initial phasic and secondary tonic contractions of the
electrically stimulated prostatic portion from adult rat vas defe-
rens are diminished. The increase of noradrenaline concentra-
tion induced by the blockade of uptake process also activate
α2-adrenoceptors, inducing a decrease in the initial phasic con-
traction (decrease in the ATP release and initial phasic component)
as well as in the secondary tonic contraction because the activa-
tion α2-adrenoceptors overrides the postsynaptic effects of nora-
drenaline in the prostatic-half (Ventura, 1998). Therefore, the
decrease of the neurogenic evoked contractions of young rat vas
deferens acutely treated with sibutramine could be due to the
interference of this drug in the uptake process.
Phenylephrine is an agonist of α1-adrenoceptors (Minneman et
al., 1994) and, approximately, 8.5-fold less susceptible to uptake
system than noradrenaline (Iversen, 1967). From cumulative con-
centration–response curves for this agonist, we found a slight
leftward shift (by about 4-fold) and unaltered maximal response in
young rats acutely treated with sibutramine. The leftward shift of
phenylephrine curves found in vas deferens from young treated
rats can be explained by the interference of uptake system induced
by sibutramine.
However, the unaltered maximal response for phenylephrine is
an unexpected result once several studies indicated that the in vivo
or in vitro treatment with sibutramine increased the maximal
response for noradrenaline as well as the calcium sensitivity in
vas deferens and seminal vesicle (Nojimoto et al., 2009; Jurkiewicz
et al., 2012). Such differences could be related to the individual
properties of this drug, for instance: (a) phenylephrine is able to
induce the generation of nitric oxide in rat vas deferens (Pinto et al.,
2002), therefore, the maximal response to this drug could be
impaired by the inhibitory contractile effects induced by nitric
oxide; or (b) phenylephrine has substantial bias toward extracellular
acidiﬁcation rate versus calcium release, compared to noradrenaline
at α1A-adrenoceptors (Evans et al., 2011), which is the most
important subtype of adrenoceptors present in the rat vas deferens
(Avellar et al., 2009). The exact mechanism related to the unaltered
maximal effect of phenylephrine after the acute treatment with
subutramine is unknown and needs further investigation.
In conclusion, the pharmacological assays showed that the
acute treatment with sibutramine in young rats was able to affect
the peripheral sympathetic nervous system by inhibition of
noradrenaline uptake and reduction of the neuronal content of
this neurotransmitter, leading to an enhancement of vas deferens
sensitivity to noradrenaline and consequently increase of contrac-
tile response of this tissue. Once vas deferens smooth muscle
contraction is responsible for the mechanism of sperm transport
from the epididymis cauda to urethra not only during ejaculation
but also at rest (Hamilton et al., 1972), it is expected that
alterations in vas deferens contractility may cause subfertility
related to the impairment of transport and sperm emission
(Bruschini et al., 1977; Anton et al., 1977). Furthermore, consider-
ing that sibutramine is still prescribed in some countries for the
management of obesity among adolescents, the present study may
subsidize further investigation to check whether this scenario
could cause permanent impairments to male reproduction func-
tion of these youngsters.
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